Medivation Inc. (MDVN): Today's Featured Health Care Laggard
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model
.
(
) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day up 0.1%. By the end of trading, Medivation fell $1.15 (-2.4%) to $46.26 on average volume. Throughout the day, one million shares of Medivation exchanged hands as compared to its average daily volume of 943,800 shares. The stock ranged in price between $45.97-$48.01 after having opened the day at $47.81 as compared to the previous trading day's close of $47.41. Other companies within the Health Care sector that declined today were:
(
), down 20.9%,
(
), down 19.7%,
(
), down 16.3%, and
(
), down 12.7%.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Medivation, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for the treatment of serious diseases in the United States and Europe. Medivation has a market cap of $3.5 billion and is part of the drugs industry. The company has a P/E ratio of -128.4, below the S&P 500 P/E ratio of 17.7. Shares are up 106% year to date as of the close of trading on Monday. Currently there are seven analysts that rate Medivation a buy, no analysts rate it a sell, and one rates it a hold.
TheStreet Ratings rates Medivation as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and increase in net income. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow, generally higher debt management risk and feeble growth in the company's earnings per share.
- You can view the full Medivation Ratings Report.
On the positive front,
(
), up 74.6%,
(
), up 61.4%,
(
), up 25%, and
(
), up 17.3%, were all gainers within the health care sector with
(
) being today's featured health care sector leader.
- Use our health care section to find sector-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider
Health Care Select Sector SPDR
(
) while those bearish on the health care sector could consider
ProShares Ultra Short Health Care
(
).
- Find other investment ideas from our top rated ETFs lists.
FREE for a limited time only: Get TheStreet Ratings #1 Stock Report NOW!
.
null